

Pierre Laurent-Puig, MD, PhD

Pierre Laurent-Puig is Professor at the Paris - Descartes University Medical School, France. He works within the department of Biochemistry at the European Georges Pompidou Hospital Paris, where he is responsible for the Clinical Oncogenetic Unit in the Department of Genetics and he is also Director since 2004 of UMR-S775 INSERM laboratory entitled Molecular Basis of the Response to Xenobiotic at the Paris Decartes University.

Following specialist clinical training in gastroenterology, liver disease and digestive tract cancer, Dr. Laurent-Puig embarked upon doctoral and post-doctoral research work in INSERM Unit 434 under the direction of G. Thomas at the Curie Institute in Paris, where his research activities focused on the characterisation of somatic genetic lesions in cancer. His later works addressed the identification of new diagnostic and prognostic markers, and more recently, markers for resistance to chemotherapy and targeted therapy. Initially, the work focused exclusively on colon cancer and hepatocellular carcinoma but more recently it has been extended to cover malignancies involving the head and neck and lung.

Dr. Laurent-Puig's has (co)authored 44 educational articles and 140 original scientific publications in international, peer-reviewed journals, including *Nature*, *Nature Genetics*, the *New England Journal of Medicine*, *Gastroenterology*, the *Journal of Clinical Oncology*, the *Proceedings of the National Academy of Sciences*, *Cancer Research*, *Hepatology*, *Oncogene*, *Clinical Cancer Research*, the *International Journal of Cancer* and the *British Journal of Cancer*. The number of citation is 9688 and his h index is 48

Dr. Laurent-Puig is an active member of several professional organizations, including the American Association for Cancer Research (AACR) and the French Society of Hepatogastroenterology. He is also a member of the board of the Fédération Francophone de Cancérologie Digestive (FFCD) and the gastrointestinal translational research group of the European Organization for Research and Treatment of Cancer (EORTC).

Recent publications:

Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. ***Clin Cancer Res***. 2009;15:1133-9.

Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. KRAS Mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. ***J Clin Oncol*** 2008;26:374-9

Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P*, Ychou M*. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. ***Clin Cancer Res***. 2007;13:3269-75. * equally contributed

Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. ***Cancer Res***. 2006;66:3992-5.

Lecomte T, Landi B, Beaune P, Laurent-Puig P, Lorient MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. ***Clin Cancer Res***. 2006;12:3050-6

Lièvre A, Chapusot C, Bouvier AM, Zinzindohoué F, Piard F, Roignot P, Arnould L, Beaune P, Faivre J, Laurent-Puig P. Clinical value of mitochondrial mutations in colorectal cancer. ***J Clin Oncol***. 2005;23:3517-25.

Zinzindohoué F, Lecomte T, Ferraz JM, Houllier AM, Cugnenc PH, Berger A, Blons H, Laurent-Puig P. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. ***Clin Cancer Res***. 2005;11:594-9.

Lecomte T, Ferraz JM, Zinzindohoué F, Lorient MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. ***Clin Cancer Res***. 2004;10:5880-8.

Blons H, Gad S, Zinzindohoué F, Manière I, Beauregard J, Tregouet D, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. ***Clin Cancer Res***. 2004;10:2594-9.

Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. ***N Engl J Med***. 2003;349:247-57.

Laurent-Puig P, Plomteux O, Bluteau O, Zinzindohoué F, Jeannot E, Dahan K, Kartheuser A, Chapusot C, Cugnenc PH, Zucman-Rossi J. Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability. ***Gastroenterology***. 2003;124:1311-4.

Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. **J Clin Oncol.** 2000;18:1465-73.

Coulet F, Blons H, Cabelguenne A, Lecomte T, Lacourreye O, Brasnu D, Beaune P, Zucman J, Laurent-Puig P. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. **Cancer Res.** 2000;60:707-11.